OncoMatch/Clinical Trials/NCT05039801
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Is NCT05039801 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Bevacizumab and Glutaminase-1 Inhibitor IACS-6274 for advanced endometrial carcinoma.
Treatment: Bevacizumab · Glutaminase-1 Inhibitor IACS-6274 · Paclitaxel · Capivasertib — To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Head and Neck Squamous Cell Carcinoma
Tumor Agnostic
Melanoma
Ovarian Cancer
Biomarker criteria
Required: KEAP1 actionable mutation
Patients with tumors harboring actionable KEAP1/NFE2L2/STK11/NF1 mutations
Required: NFE2L2 actionable mutation
Patients with tumors harboring actionable KEAP1/NFE2L2/STK11/NF1 mutations
Required: STK11 actionable mutation
Patients with tumors harboring actionable KEAP1/NFE2L2/STK11/NF1 mutations
Required: NF1 actionable mutation
Patients with tumors harboring actionable KEAP1/NFE2L2/STK11/NF1 mutations
Required: ASNS low expression (low)
Patients with low ASNS expression levels (HGSOC or endometrial cancer)
Required: ARID1A mutation
Patients with ARID1A mutant clear cell ovarian cancer
Required: PIK3CA hotspot mutation
Patients with tumors harboring PIK3CA hotspot mutations
Required: AKT1 activating mutation
Patients with tumors harboring ... activating AKT mutations
Required: PTEN inactivating mutation
Patients with tumors harboring ... inactivating PTEN mutations
Disease stage
Required: Stage CLINICAL STAGE III AJCC V8, CLINICAL STAGE IV AJCC V8, PATHOLOGIC STAGE III AJCC V8, PATHOLOGIC STAGE IIIA AJCC V8, PATHOLOGIC STAGE IIIB AJCC V8, PATHOLOGIC STAGE IIIC AJCC V8, PATHOLOGIC STAGE IIID AJCC V8, PATHOLOGIC STAGE IV AJCC V8, STAGE III AJCC V8, STAGE IIIA AJCC V8, STAGE IIIA1 AJCC V8, STAGE IIIA2 AJCC V8, STAGE IIIB AJCC V8, STAGE IIIC AJCC V8, STAGE IIIC1 AJCC V8, STAGE IIIC2 AJCC V8, STAGE IV AJCC V8, STAGE IVA AJCC V8, STAGE IVB AJCC V8 (AJCC v8)
Histologically or cytologically confirmed advanced solid tumors, specifically: ... (see full list in conditions)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: any systemic therapy — advanced stage disease
Patients must have received at least one line of therapy for advanced stage disease and be refractory or ineligible to available existing therapy(ies) known to provide clinical benefit for their condition.
Lab requirements
Blood counts
ANC ≥1.0×10^9/L; Platelets ≥100×10^9/L; Hemoglobin ≥9.0 g/dL
Kidney function
Creatinine clearance (CrCl) >50 mL/min (Cockroft Gault equation)
Liver function
Serum total bilirubin ≤1.5×ULN (≤3×ULN for thalassemia minor or Gilbert's syndrome); AST/ALT ≤2.5×ULN or ≤5×ULN for patients with liver metastases
Cardiac function
Left ventricular ejection fraction ≥50%
Adequate organ function as indicated by the following laboratory values: ... Adequate cardiac function with a left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify